Making a diagnosis of acute myeloid leukaemia (AML) requires a multi-faceted approach bringing together clinical features of patient presentation with laboratory investigations encompassing morphological, immunophenotypic and genetic evaluation of blood, bone marrow and, when appropriate, cerebrospinal fluid (CSF). Recent years have seen updates in disease classification and risk stratification, the rapid incorporation of novel laboratory techniques into routine practice and significant changes in treatment algorithms brought about by the approval of a range of new therapeutic agents.
Declaration of Interests
The BSH paid the expenses incurred during the writing of this good practice paper. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.